Processa Pharmaceuticals, Inc.
PCSA
$0.218
$0.0115.31%
NASDAQ
| 06/30/2025 | 03/31/2025 | ||||
|---|---|---|---|---|---|
| Revenue | -- | -- | |||
| Total Other Revenue | -- | -- | |||
| Total Revenue | -- | -- | |||
| Cost of Revenue | -- | -- | |||
| Gross Profit | -- | -- | |||
| SG&A Expenses | 19.47% | 23.10% | |||
| Depreciation & Amortization | -- | -- | |||
| Other Operating Expenses | -- | -- | |||
| Total Operating Expenses | 38.77% | 4.11% | |||
| Operating Income | -38.77% | -4.11% | |||
| Income Before Tax | -38.79% | -3.87% | |||
| Income Tax Expenses | -- | -- | |||
| Earnings from Continuing Operations | -38.79% | -3.87% | |||
| Earnings from Discontinued Operations | -- | -- | |||
| Extraordinary Item & Accounting Change | -- | -- | |||
| Minority Interest in Earnings | -- | -- | |||
| Net Income | -38.79% | -3.87% | |||
| EBIT | -38.77% | -4.11% | |||
| EBITDA | -38.77% | -4.11% | |||
| EPS Basic | 15.06% | 61.74% | |||
| Normalized Basic EPS | 15.06% | 61.74% | |||
| EPS Diluted | 15.06% | 61.74% | |||
| Normalized Diluted EPS | 15.06% | 61.74% | |||
| Average Basic Shares Outstanding | 63.43% | 171.43% | |||
| Average Diluted Shares Outstanding | 63.43% | 171.43% | |||
| Dividend Per Share | -- | -- | |||
| Payout Ratio | -- | -- | |||